Neurotech products generated revenues of $110 bln in 2005 with 10% growth. The three sectors contributed as follows: neuropharmaceuticals with revenues of $93 bln and 7% growth; neurodevices with revenues of $3.4 bln and 21% growth; and neurodiagnostics with revenues of $13.5 bln and 11% growth. Venture capital investment in neurotech companies climbed 230% from 1999 to 2005, representing nearly $7.5 bln. Today, 25% of VC dollars invested in life sciences goes to neurotechnology companies, NeuroInsights said.